TY - JOUR
T1 - Latitude and Celiac Disease Prevalence
T2 - A Meta-Analysis and Meta-Regression
AU - Celdir, Melis G.
AU - Jansson-Knodell, Claire L.
AU - Hujoel, Isabel A.
AU - Prokop, Larry J.
AU - Wang, Zhen
AU - Murad, M. Hassan
AU - Murray, Joseph A.
N1 - Funding Information:
Conflicts of interest This author discloses the following: Joseph A. Murray receives grant support from Nexpep/ImmusanT, Inc, National Institutes of Health, Immunogenix, Takeda Pharmaceutical, Inc, Allakos, Inc, Oberkotter Foundation, and Cour, Inc, is a consultant to Bionix, Lilly Research Laboratory, Johnson & Johnson, Dr. Schar USA, Inc, UCB Biopharma, Innovate Biopharmaceuticals, Glenmark Pharmaceuticals, Celimmune, Amgen Intrexon Corporation, Kanyos, and Boehringer Ingelheim, holds patents licensed to Evelo Biosciences, Inc, and receives royalties from Torax Medical. The remaining authors disclose no conflicts.
Funding Information:
The authors thank the Mayo Clinic Editing Services for writing assistance. Conflicts of interest This author discloses the following: Joseph A. Murray receives grant support from Nexpep/ImmusanT, Inc, National Institutes of Health, Immunogenix, Takeda Pharmaceutical, Inc, Allakos, Inc, Oberkotter Foundation, and Cour, Inc, is a consultant to Bionix, Lilly Research Laboratory, Johnson & Johnson, Dr. Schar USA, Inc, UCB Biopharma, Innovate Biopharmaceuticals, Glenmark Pharmaceuticals, Celimmune, Amgen Intrexon Corporation, Kanyos, and Boehringer Ingelheim, holds patents licensed to Evelo Biosciences, Inc, and receives royalties from Torax Medical. The remaining authors disclose no conflicts.
Publisher Copyright:
© 2022 AGA Institute
PY - 2022/6
Y1 - 2022/6
N2 - Background & Aims: The latitudinal gradient effect is described for several autoimmune diseases including celiac disease in the United States. However, the association between latitude and global celiac disease prevalence is unknown. We aimed to explore the association between latitude and serology-based celiac disease prevalence through meta-analysis. Methods: We searched MEDLINE, Embase, Cochrane, and Scopus databases from their beginning through June 29, 2018, to identify screening studies that targeted a general population sample, used serology-based screening tests, and provided a clear location from which we could assign a latitude. Studies were excluded if sampling was based on symptoms, risk factors, or referral. Study selection and data extraction were performed by independent reviewers. The association measures between latitude and prevalence of serology-based celiac disease were evaluated with random-effects meta-analyses and meta-regression. Results: Of the identified 4667 unique citations, 128 studies were included, with 155 prevalence estimates representing 40 countries. Celiac disease was more prevalent at the higher latitudes of 51° to 60° (relative risk [RR], 1.62; 95% CI, 1.09–2.38) and 61° to 70° (RR, 2.30; 95% CI, 1.36–3.89) compared with the 41° to 50° reference level. No statistically significant difference was observed at lower latitudes. When latitude was treated as continuous, we found a statistically significant association between CD prevalence and latitude overall in the world (RR, 1.03, 95% CI, 1.01–1.05) and a subregional analysis of Europe (RR, 1.05; 95% CI, 1.02–1.07) and North America (RR, 1.1; 95% CI, 1.0–1.2). Conclusions: In this comprehensive review of screening studies, we found that a higher latitude was associated with greater serology-based celiac disease prevalence.
AB - Background & Aims: The latitudinal gradient effect is described for several autoimmune diseases including celiac disease in the United States. However, the association between latitude and global celiac disease prevalence is unknown. We aimed to explore the association between latitude and serology-based celiac disease prevalence through meta-analysis. Methods: We searched MEDLINE, Embase, Cochrane, and Scopus databases from their beginning through June 29, 2018, to identify screening studies that targeted a general population sample, used serology-based screening tests, and provided a clear location from which we could assign a latitude. Studies were excluded if sampling was based on symptoms, risk factors, or referral. Study selection and data extraction were performed by independent reviewers. The association measures between latitude and prevalence of serology-based celiac disease were evaluated with random-effects meta-analyses and meta-regression. Results: Of the identified 4667 unique citations, 128 studies were included, with 155 prevalence estimates representing 40 countries. Celiac disease was more prevalent at the higher latitudes of 51° to 60° (relative risk [RR], 1.62; 95% CI, 1.09–2.38) and 61° to 70° (RR, 2.30; 95% CI, 1.36–3.89) compared with the 41° to 50° reference level. No statistically significant difference was observed at lower latitudes. When latitude was treated as continuous, we found a statistically significant association between CD prevalence and latitude overall in the world (RR, 1.03, 95% CI, 1.01–1.05) and a subregional analysis of Europe (RR, 1.05; 95% CI, 1.02–1.07) and North America (RR, 1.1; 95% CI, 1.0–1.2). Conclusions: In this comprehensive review of screening studies, we found that a higher latitude was associated with greater serology-based celiac disease prevalence.
KW - Epidemiology
KW - Serum
KW - Sprue
KW - Tissue Transglutaminase
UR - http://www.scopus.com/inward/record.url?scp=85103962176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103962176&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2020.09.052
DO - 10.1016/j.cgh.2020.09.052
M3 - Review article
C2 - 33007509
AN - SCOPUS:85103962176
SN - 1542-3565
VL - 20
SP - e1231-e1239
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 6
ER -